Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-PMAT Immunotherapy for Postoperative Hepatocellular Carcinoma
NCT02632188Phase 2Unknown
- Sponsor
- Naval Medical University
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Precision Multiple Antigen T Cell in hepatocellular carcinoma (HCC) (2 arms), sponsored by Naval Medical University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Precision Multiple Antigen T Cell
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02632188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632188.